Trial Profile
An Open-label Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Hyaluronidase
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Shire
- 23 Apr 2014 New trial record